Ventyx Biosciences, Inc. (VTYX)
NASDAQ: VTYX · Real-Time Price · USD
1.210
-0.020 (-1.63%)
Mar 28, 2025, 4:00 PM EDT - Market closed

Ventyx Biosciences Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2019
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2019
Selling, General & Admin
31.4532.2325.48.670.68
Upgrade
Research & Development
117175.7787.7458.486.37
Upgrade
Operating Expenses
148.45207.99113.1467.157.05
Upgrade
Operating Income
-148.45-207.99-113.14-67.15-7.05
Upgrade
Interest Expense
----0.1-0.36
Upgrade
Interest & Investment Income
13.4215.074.670.08-
Upgrade
Other Non Operating Income (Expenses)
-0.09-0.040.04-16.58-20.77
Upgrade
Pretax Income
-135.12-192.96-108.43-83.75-28.17
Upgrade
Net Income
-135.12-192.96-108.43-83.75-28.17
Upgrade
Preferred Dividends & Other Adjustments
---1.55-
Upgrade
Net Income to Common
-135.12-192.96-108.43-85.3-28.17
Upgrade
Shares Outstanding (Basic)
685952132
Upgrade
Shares Outstanding (Diluted)
685952132
Upgrade
Shares Change (YoY)
16.97%11.57%309.11%544.96%19.64%
Upgrade
EPS (Basic)
-1.97-3.30-2.07-6.65-14.17
Upgrade
EPS (Diluted)
-1.97-3.30-2.07-6.65-14.17
Upgrade
Free Cash Flow
-131.11-167.04-99.05-38.91-6.2
Upgrade
Free Cash Flow Per Share
-1.92-2.85-1.89-3.03-3.12
Upgrade
EBITDA
-148.18-207.84-113.01-67.12-
Upgrade
D&A For EBITDA
0.270.160.120.03-
Upgrade
EBIT
-148.45-207.99-113.14-67.15-7.05
Upgrade
Updated Feb 27, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q